首页> 外文期刊>Molecular cancer therapeutics >Antitumor activity of fibroblast growth factor receptor 3-specific immunotoxins in a xenograft mouse model of bladder carcinoma is mediated by apoptosis.
【24h】

Antitumor activity of fibroblast growth factor receptor 3-specific immunotoxins in a xenograft mouse model of bladder carcinoma is mediated by apoptosis.

机译:成纤维细胞生长因子受体3特异性免疫毒素在膀胱癌异种移植小鼠模型中的抗肿瘤活性是由细胞凋亡介导的。

获取原文
获取原文并翻译 | 示例
           

摘要

Human single-chain Fv directed against fibroblast growth factor receptor 3 (FGFR3) have been shown to block proliferation of RT112 bladder carcinoma cells in vitro. Here, we examined the ability of the recombinant gelonin toxin (rGel) to enhance this inhibitory effect in vitro and in vivo on the bladder cancer cell line RT112 and the corresponding xenografts. Immunotoxins were genetically engineered by fusing FGFR3-specific Fv fragments (3C) to the NH(2) terminus of rGel and expressed as a soluble protein in Escherichia coli. The 3C/rGel fusion construct showed an IC(50) of 200 nmol/L against log-phase RT112 cells compared with 1,500 nmol/L for free rGel. Immunofluorescence studies showed that the 3C/rGel construct internalized rapidly into the cytoplasm of RT112 cells within 1 h of exposure. The mechanism of immunotoxin-induced cell death was found to be mediated by apoptosis. RT112 tumor xenografts in severe combined immunodeficient mice treated with 50 mg/kg 3C/rGel exhibited considerable growth delay relative to control tumors and a significant reduction of 55% to 70% in mean tumor size. Immunohistochemical analysis showed that tumors from mice treated with 3C/rGel displayed considerable apoptotic damage compared with control groups. Subcellular location of FGFR3 in immunotoxin-treated tumors indicated a translocation of FGFR3 to the nuclear membrane in contrast to tumors from saline-treated controls. These results show that FGFR3-driven immunotoxins may be an effective therapeutic agent against human bladder and other tumor types overexpressing FGFR3.
机译:已经表明,针对成纤维细胞生长因子受体3(FGFR3)的人单链Fv可以在体外阻断RT112膀胱癌细胞的增殖。在这里,我们检查了重组明胶毒素(rGel)在体外和体内增强对膀胱癌细胞系RT112和相应异种移植物的抑制作用的能力。通过将FGFR3特异的Fv片段(3C)融合到rGel的NH(2)末端进行遗传工程改造,从而获得免疫毒素,并在大肠杆菌中表达为可溶性蛋白。 3C / rGel融合构建体显示对数期RT112细胞的IC(50)为200 nmol / L,而游离rGel的IC(50)为1,500 nmol / L。免疫荧光研究表明,3C / rGel构建体在暴露后1小时内迅速内化到RT112细胞的细胞质中。发现免疫毒素诱导的细胞死亡的机制是由凋亡介导的。在用50 mg / kg 3C / rGel处理的严重联合免疫缺陷小鼠中,RT112肿瘤异种移植物相对于对照肿瘤显示出显着的生长延迟,并且平均肿瘤大小显着降低了55%至70%。免疫组织化学分析显示,与对照组相比,用3C / rGel处理的小鼠肿瘤显示出明显的凋亡损伤。 FGFR3在免疫毒素治疗的肿瘤中的亚细胞定位表明,与盐水治疗对照组的肿瘤相比,FGFR3易位至核膜。这些结果表明,FGFR3驱动的免疫毒素可能是抗人膀胱和其他过度表达FGFR3的肿瘤的有效治疗剂。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号